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Background: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative
combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous
studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell
cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged
xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.
Methods: KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or
forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B
assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and
combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange
staining. Protein expressions were determined by Western blot analysis.
Results: Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and
showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination
showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin
combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of
apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments.
The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while
suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments.
The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction
of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups
than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly
higher in the combined treatment than in the single drug treatment groups.
Conclusion: The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic
effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be
useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.
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Cholangiocarcinoma (CCA) is a tumor arising from the
bile duct epithelium. The worldwide incidence and mor-
tality rate of CCA are increasing [1,2]. This cancer has a
poor prognosis because the majority of patients are diag-
nosed at a late stage and the tumor often recurs after
surgery [3]. The treatment option for advanced CCA is
chemotherapy [4]. Doxorubicin is one of the chemother-
apeutic drugs used to treat CCA [4], but it is known to
(a) be highly toxic to normal tissues; (b) cause immuno-
suppression and secondary cardiomyopathy; and (c) en-
gender the drug resistance of tumor cells, thereby limiting
its efficacy [5,6]. Chemotherapeutic drugs induce apop-
tosis through DNA damage and cell cycle arrest. However,
defects in oncogene activation and/or the deregulation of
apoptotic signaling pathways are common in cancer cells,
allowing them to evade apoptosis [7]. In CCA, increased
expression levels of Bcl-2 and survivin (anti-apoptotic pro-
teins) are frequently observed and are associated with
tumor progression and aggressiveness [8,9], while the
overexpression of Mcl-1 and survivin is associated with
drug resistance [10,11]. The activation of nuclear factor-
kappa B (NF-κB), a key transcriptional regulator of genes
involved in cell survival, proliferation and apoptosis induc-
tion, was found to be associated with CCA development
in an animal model [12], and high expression levels of
NF-κB in CCA patient tissues have also been reported
[Seubwai et al., manuscript in preparation]. Enhanced
expression of the ATP-binding cassette transporters of
the multidrug resistance protein families MDR and MDR-
associated proteins (MRPs) in cancer cells is a major cause
of multidrug resistance both in vitro and in vivo [13]. The
P-glycoprotein (P-gp) and MRP1-3 are expressed in cho-
langiocytes [14,15], and their overexpression is associated
with drug resistance in CCA. Consequently, alternative
adjunct therapies for CCA are urgently needed.
Plant-derived caged xanthones are potential adjunct
therapies to existing chemotherapeutic strategies. Gam-
bogic acid, a caged xanthone, was reported to overcome
the docetaxel resistance of gastric cancer BGC-823/Doc
cells [16] and to enhance 5-fluorouracil (5-FU)-induced
apoptosis in human gastric cancer BGC-823 cells [17].
Han and Xu [18] reported that, among the caged xan-
thones isolated from Garcinia hanburyi, gambogic acid
is the most extensively studied compound, with promis-
ing anticancer effects against a variety of cancer cell lines
both in vitro and in vivo [19,20]. Multiple mechanisms
have been proposed for gambogic acid-induced anticancer
activities, including the induction of apoptosis [19], sup-
pression of telomerase activity [21], induction of cell-cycle
arrest [22], inhibition of cancer metastasis and angiogenesis
[20,23], inhibition of topoisomerase IIα activity [24] and in-
hibition of the NF-κB signaling pathway [25]. In various
animal models, gambogic acid is well tolerated, suggestingthe existence of a therapeutic approach for its use [26,27].
Gambogic acid injection was recently approved by the
Chinese State Food and Drug Administration as an antitu-
mor treatment and will enter phase II clinical trials [28].
We report that four caged xanthones; isomorellin,
gambogic acid, forbesione and isomorellinol, have a se-
lective inhibitory effect against the growth of the CCA
cell lines KKU-100 and KKU-M156. These caged xan-
thones induce mitochondrial apoptosis pathways [29]
and induce cell cycle arrest at G0/G1 phase [30]. These
results suggest that caged xanthones could be used in
combination therapy due to their low toxicity to normal
cells and multiple targeted effects [29,30].
To date, the effects of caged xanthones combined with
conventional chemotherapeutic drugs have not been evalu-
ated for the treatment of human CCA. Therefore, we exam-
ined the effects of combining caged xanthones (isomorellin
and forbesione) with doxorubicin compared with their indi-
vidual activities against CCA KKU-100, KKU-M139 and
KKU-M156 cells in vitro. We also investigated the possible
mechanisms of any observed synergistic effects.
Results
Inhibition of cholangiocarcinoma cell growth by
isomorellin, forbesione and doxorubicin
The inhibitory effects of isomorellin, forbesione and
doxorubicin on the growth of CCA cell lines and Chang
cells were evaluated using the sulforhodamine B (SRB)
assay. After exposure to these compounds and doxorubi-
cin, the growth of KKU-100, KKU-M139, KKU-M156
and Chang cells was inhibited in a dose-dependent man-
ner (Figure 1). The IC50 value of isomorellin in Chang
cells was 22.2-, 27.4- and 32.8-fold higher than that in
KKU-100, KKU-M139 and KKU-M156 cells, respectively
(Table 1). Similarly, the IC50 value of forbesione in Chang
cells was 3.7-, 5.7- and 4.9-fold higher than that in
KKU-100, KKU-M139 and KKU-M156 cells, respect-
ively (Table 1). These results indicate a selective growth
suppression effect of these compounds on cancer cells.
When KKU-100, KKU-M139 and KKU-M156 cells were
treated with isomorellin, forbesione or doxorubicin, the
IC50 values for each compound were different, and KKU-
M156 cells were more susceptible than KKU-100 and
KKU-M139 cells to all three compounds (Table 1). The
dose ranges of isomorellin and/or doxorubicin or forbe-
sione and/or doxorubicin were determined for further
study in accordance with the IC50 values for each cell line.
Effects of isomorellin or forbesione in combination with
doxorubicin on cell growth
The combined effects of isomorellin/doxorubicin or forbe-
sione/doxorubicin on the growth inhibition of KKU-100,
KKU-M139, KKU-M156 and Chang cells were determined



































































































































































































































































Figure 1 Growth inhibitory effects of caged xanthones and doxorubicin on KKU-100, KKU-M139, KKU-M156 and Chang cells. Cells were
treated with DMSO or with the indicated concentrations of isomorellin, forbesione and doxorubicin for 72 h. Data are presented as the mean ± SE
of three independent experiments. aP < 0.05, bP < 0.01, cP < 0.001 vs. DMSO-treated cells.
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http://www.cancerci.com/content/14/1/68combined effects were (a) the dose reduction index (DRI),
(b) the combination index (CI) and (c) the dose-effect levels
of cell growth inhibition at the 50%, 75% and 90% inhibitory
concentrations (IC50, IC75 and IC90) (Table 2). The com-
bination of isomorellin/doxorubicin in KKU-M156 and
KKU-M139 cells was synergistic, but this combination
was antagonistic in KKU-100 cells. The combination ofTable 1 IC50 values of the caged xanthones and
doxorubicin in cholangiocarcinoma cells and Chang cells
Compounds IC50 value (μM)
KKU-100 KKU-M139 KKU-M156 Chang
Isomorellin 3.34 ± 0.12 2.71 ± 0.10 2.26 ± 0.05 74.19 ± 0.39
Forbesione 3.53 ± 0.05 2.29 ± 0.04 2.63 ± 0.05 13.13 ± 0.57
Doxorubicin 0.06 ± 0.02 3.74 ± 0.08 0.007 ± 0.002 13.65 ± 0.41
Mean ± SE of three independent experiments.isomorellin/doxorubicin in KKU-M156 cells was synergis-
tic at all three dose levels, with respective CIs of 0.92, 0.47
and 0.24 (Figure 2 and Table 2). The combination of iso-
morellin/doxorubicin showed a synergistic inhibitory ef-
fect on the growth of KKU-M139 cells at low and medium
concentrations (IC50 and IC75), with respective CIs of 0.80
and 0.92 (Figure 2 and Table 2). The combination of for-
besione/doxorubicin in KKU-100 and KKU-M139 cells
was synergistic, but the combination was antagonistic in
KKU-M156 cells. The combination of forbesione/doxo-
rubicin in KKU-100 cells was synergistic at medium and
high concentrations (IC75 and IC90) with CIs of 0.69 and
0.39, respectively (Figure 2 and Table 2). The combination
of forbesione/doxorubicin showed a synergistic inhibitory
effect on the growth of KKU-M139 cells at all three doses,
with CIs of 0.46, 0.55 and 0.65, respectively (Figure 2 and
Table 2). Both combinations of isomorellin/doxorubicin
Table 2 Dose-effect relationships of isomorellin, forbesione and doxorubicin combinations in cholangiocarcinoma cell
lines
Cell line Single compounds,
drug & combinations
Parameter CI value DRI value
r IC50 IC75 IC90 IC50 IC75 IC90
KKU-M156 Isomorellin 0.86 29.65 53.54 96.69
Doxorubicin 0.91 1.12 2.18 4.23
(D)1 + (D)2 (1 : 1.25) 0.97 0.92 0.47 0.24
KKU-100 Forbesione 0.88 4.46 8.32 15.51
Doxorubicin 0.88 1.00 1.73 2.99
(D)1 + (D)2 (1 : 0.25) 0.98 1.21 0.69 0.39
KKU-M139 Isomorellin 0.93 2.15 1.89 1.66
Doxorubicin 0.94 3.04 2.57 2.17
(D)1 + (D)2 (2 : 1) 0.81 0.80 0.92 1.06
Forbesione 0.89 3.28 2.83 2.44
Doxorubicin 0.89 6.57 5.20 4.12
(D)1 + (D)2 (2 : 1) 0.85 0.46 0.55 0.65
Dose-effect relationships calculated using the median-effect equation. The r linear correlation is the coefficient of the median effect plot (indicates conformity of
data). CIs were calculated using Chou and Talalay’s CI equation. The DRI dose reduction index was measured by comparing doses required to reach a given degree
of inhibition when using compound(s) or drug as a single agent and/or in combination.
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cells at all doses examined (CI > 1) (Figure 2).
As a result of the observed synergy between caged xan-
thones and doxorubicin, there was a considerable reduc-
tion in the DRI (Table 2). At dose levels corresponding to
synergistic drug combinations, the DRI indicated that the
doxorubicin concentration needed to inhibit 90% of the
growth of cancer cells (IC90) could be decreased 4.23-
fold (KKU-M156, isomorellin/doxorubicin), 2.99-fold
(KKU-100, forbesione/doxorubicin), 2.17-fold (KKU-
M139, isomorellin/doxorubicin) and 4.12-fold (KKU-
M139, forbesione/doxorubicin) (Table 2).
Synergistic effects of isomorellin/doxorubicin and
forbesione/doxorubicin combinations on the induction of
apoptosis in CCA cell lines
In our previous study [29], isomorellin and forbesione were
found to induce apoptosis in KKU-100 and KKU-M156
cell lines through the mitochondrial pathway. When the
combined effects of isomorellin/doxorubicin or forbesione/
doxorubicin on the inhibition of growth in KKU-100,
KKU-M139, KKU-M156 and Chang cells were examined,
the highest synergistic effect was observed in KKU-M156
cells treated with the isomorellin/doxorubicin combin-
ation (CI value at IC90 = 0.24) and in KKU-100 cells
treated with the forbesione/doxorubicin combination (CI
value at IC90 = 0.39) (Table 2). To examine the synergistic
effects of the isomorellin/doxorubicin and forbesione/
doxorubicin combinations on the induction of apoptosis in
CCA cell lines, KKU-M156 cells were treated with isomor-
ellin and/or doxorubicin, while KKU-100 cells were treated
with forbesione and/or doxorubicin at concentrations thatdemonstrated a synergistic effect. The apoptotic cells were
determined by EB/AO staining and the percentage of
apoptotic cells of 500 cells was calculated. Treatment with
isomorellin, forbesione or doxorubicin alone increased
apoptosis in both CCA cell lines, and the combination
treatment augmented apoptosis in both groups (Figures 3A
and C). The percentage of apoptotic cells was significantly
higher in the isomorellin/doxorubicin-treated KKU-M156
cells compared to cells treated with either drug alone
(Figure 3B). Similarly, a significantly higher percentage
of apoptotic cells were observed in the forbesione/
doxorubicin-treated KKU-100 cells than in cells treated
with either drug alone (Figure 3D).
Isomorellin/doxorubicin and forbesione/doxorubicin
treatments modulate the expression of apoptosis
regulating protein in CCA cell lines
To determine the possible molecular mechanisms of the
synergistic induction of apoptosis in cells treated with the
isomorellin/doxorubicin and forbesione/doxorubicin com-
binations, the expression levels of mitochondrial apoptosis
regulating proteins were determined using Western blot
analysis. When KKU-M156 cells were treated with either
isomorellin or doxorubicin or a combination of these two
drugs, the expression of Bcl-2 protein was significantly
decreased, whereas Bax protein expression was significantly
increased in a dose-dependent manner, particularly in cells
treated with the combination of both drugs (Figure 4A).
Bcl-2 expression decreased by 0.41-fold in cells treated with
combination 3 (C3) (0.031 μM doxorubicin + 0.25 μM
isomorellin), which was significantly less than that of
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Figure 2 Caged xanthones and doxorubicin combination toxicity. KKU-100, KKU-M139, KKU-M156 and Chang cells were treated with the
appropriate concentrations of isomorellin and doxorubicin or forbesione and doxorubicin for 72 h. Combination index (CI) vs. fraction affected
(fa) plots were obtained from the median-effect analysis program (CalcuSyn, Biosoft, Cambridge, UK). Dashed lines indicate a CI of 1. Each value
represents the mean of three independent experiments.
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http://www.cancerci.com/content/14/1/68with 0.25 μM isomorellin (0.76-fold) (Table 3). In contrast,
the increase in Bax expression in cells treated with C3 was
2.13-fold compared to the control cells, and this increase
was significantly higher than that of cells treated with
doxorubicin (1.45-fold) or isomorellin (1.32-fold) alone.
Likewise, the ratio of Bax/Bcl-2 increased significantly, es-
pecially in the combination treatment group (Table 3).
Similar results were obtained when KKU-100 cells were
treated with either forbesione or doxorubicin or a combin-
ation of the two drugs. The expression of Bcl-2 decreased
significantly, while that of Bax increased significantly in a
dose-dependent manner, especially in the combination
treatment group (Figure 4B). In cells treated with combin-
ation C3, the expression of Bcl-2 decreased 0.1-fold, whichwas less than the decrease observed in cells treated with
doxorubicin (0.25-fold) or forbesione (0.27-fold) alone. By
comparison, the expression of Bax in cells treated with
combination C3 (3.24-fold) was significantly higher than
that in cells treated with doxorubicin (2.17-fold) or forbe-
sione (2.06-fold) alone (Table 4). The suppression of Bcl-2
and the enhancement of Bax resulted in a significant
increase in the ratio of Bax/Bcl-2, especially in the
combination groups (Table 4).
Isomorellin, forbesione or doxorubicin alone suppressed
the expression levels of survivin and procaspase-9 and
procaspase-3, while those treatments augmented the
expression of activated caspase-9 and caspase-3 in a
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C
Figure 3 Apoptosis induction by two caged xanthones and/or doxorubicin in cholangiocarcinoma (CCA) cell lines. A, Morphological
changes of KKU-M156 cells after treatment with DMSO, isomorellin (0.25 μM) and/or doxorubicin (0.031 μM) for 48 h. The cells were stained with
ethidium bromide and acridine orange (EB/AO) (400X). The apoptotic cells with condensed chromatin or fragmented chromatin are indicated
with arrows. B, Percentage of apoptotic cells in KKU-M156 cells treated with isomorellin and/or doxorubicin at the indicated concentration for
48 h. C, Morphological changes of KKU-100 cells after treatment with DMSO, forbesione (1 μM) and/or doxorubicin (0.025 μM) for 48 h. The cells
were stained with EB/AO. D, Percentage of apoptotic cells in KKU-100 cells treated with forbesione and/or doxorubicin at the indicated concentration
for 48 h. Data expressed as the mean± SE (n= 3). aP< 0.05, bP< 0.01, cP< 0.001 vs. DMSO-treated cells. Comparison between single drug treatment and
combined drug treatment is indicated by #P < 0.05, ###P < 0.001.
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treatments, was significantly augmented (Figures 4A &
B and Tables 3 & 4).
Isomorellin/doxorubicin and forbesione/doxorubicin
treatments suppress NF-кB/p65 activation in CCA cell lines
NF-кB is known to activate the expression of genes in-
volved in cell survival (anti-apoptotic proteins: Bcl-2,
survivin) [33] and its down-regulation is associated with
an apoptotic response [34]. The effects of isomorellin,
forbesione, doxorubicin and their combinations on the
expression of NF-кB/p65 in KKU-M156 cells were exam-
ined using Western blot analysis. Isomorellin or doxorubicin
alone significantly suppressed NF-кB/p65 protein expres-
sion, and the combined treatment (C2) was even more
effective (0.02-fold) than the individual treatments (Figure 5A
and Table 3). We further examined whether an inhibitor of
NF-кB (IкB-α) and phosphorylated IкB-α (pIкB-α) might beinvolved in the inhibition of NF-кB activation. IкB-α expres-
sion was slightly increased following isomorellin (1.25-fold)
or doxorubicin (1.21-fold) treatment, and the combined
treatment (C3) (1.40-fold) was found to be more effective
(Figure 5A and Table 3). In contrast, the pIкB-α protein
level was significantly decreased in cells treated with isomor-
ellin or doxorubicin alone or their combination (Figure 5A
and Table 3).
Similar results were obtained when KKU-100 cells were
treated with either forbesione or doxorubicin alone or in
combination. Forbesione, doxorubicin or their combin-
ation significantly enhanced IкB-α protein expression
while suppressing pIкB-α and NF-кB/p65 (Figure 5B).
The increase in IкB-α expression (1.21-fold) and the
decrease in pIкB-α (0.01-fold) and NF-кB/p65 expression
(0.01-fold) were significantly higher in cells treated with
combination C3 than in those treated with the single drug
(Figure 5B and Table 4).
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Figure 4 Effect of isomorellin, forbesione and/or doxorubicin on apoptosis regulated protein expression in CCA cells. A, KKU-M156 cells
treated with DMSO or indicated concentrations of doxorubicin or isomorellin or the combination of doxorubicin + isomorellin (C1: 0.007 + 0.06 μM,
C2: 0.015 + 0.12 μM, C3: 0.031 + 0.25 μM). B, KKU-100 cells treated with DMSO or indicated concentrations of doxorubicin or forbesione or the
combination of doxorubicin + forbesione (C1: 0.006 + 0.25 μM, C2: 0.012 + 0.5 μM, C3: 0.025 + 1 μM) for 48 h. Protein expression was determined
by Western blot analysis.
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http://www.cancerci.com/content/14/1/68Isomorellin/doxorubicin and forbesione/doxorubicin
treatments down-regulate expression of the drug-efflux
transporter protein (MRP1) in CCA cell lines
The p-glycoprotein and multidrug resistance proteins
(MRP) 1–3 are membrane pumps expressed on cholangio-
cytes [14,15], and their overexpression is associated with
drug resistance. To determine whether isomorellin, forbe-
sione, doxorubicin or their combinations modulate the cel-
lular efflux pathway, we evaluated the expression of MRP1,
the specific membrane pump. In KKU-M156 cells, doxo-
rubicin, isomorellin, or their combination (C3) significantly
suppressed the expression of the MRP1 protein by 0.57-,
0.79-, and 0.35-fold compared with the control, respectively
(Figure 5C and Table 3). The suppressive effect on MRP1
expression in the combination treatment (C3) was signifi-
cantly greater than in the single drug treatments (Table 3).Similarly, MRP1 protein expression in KKU-100 cells
was significantly decreased by treatments with doxorubi-
cin or forbesione alone or their combination (C3). This
effect was significantly greater in the combination (C3)
treatment than in the single drug treatments (Figure 5D
and Table 4).
Discussion
Chemotherapy has been used for the treatment of ad-
vanced CCA, but patient outcomes are not successful
in most cases due to drug resistance and severe side ef-
fects. Accordingly, the combination of chemotherapeutic
agents and natural compounds with distinct molecular
mechanisms is considered a promising therapeutic strat-
egy with higher clinical efficacy and better patient survival
than traditional therapy [35]. Many caged xanthones
Table 3 Fold-change of proteins in isomorellin- and/or doxorubicin-treated cells vs. DMSO-treated KKU-M156 cells
Proteins Treatments
KKU-M156 cell
Fold-changes of proteins in treated vs. control cells
Concentration of isomorellin or doxorubicin (μM)
Isomorellin 0.06 0.12 0.25
Doxorubicin 0.007 0.015 0.031
Iso + Dox C1 C2 C3
Bcl-2 Isomorellin 0.83a 0.83a 0.76a
Doxorubicin 1.00 0.95 0.82a
Iso + Dox 0.84a 0.80b,–,* 0.41c,*,*
Bax Isomorellin 1.26 1.32c 1.32c
Doxorubicin 1.20 1.33c 1.45c
Iso + Dox 1.84b 1.93c,*,* 2.13c,*,*
Bax/Bcl-2 Isomorellin 0.48c 0.50b 0.50b
Doxorubicin 0.35c 0.40b 0.51b
Iso + Dox 0.62c 1.09–,*,* 2.35c,*,*
Survivin Isomorellin 1.00 0.96 0.86
Doxorubicin 0.96 0.96 0.95
Iso + Dox 0.96 0.64b,*,* 0.02c,*,*
Procaspase-9 Isomorellin 0.88 0.84 0.74a
Doxorubicin 0.87 0.82 0.76a
Iso + Dox 0.82a 0.57b,*,* 0.39b,*,*
Activated Isomorellin 10.00c 18.00c 30.00c
caspase-9 Doxorubicin 10.00c 20.00c 24.00c
Iso + Dox 20.00c 64.00c,*,* 73.00c,*,*
Procaspase-3 Isomorellin 1.00 0.93 0.84
Doxorubicin 1.00 0.93 0.86a
Iso + Dox 0.93 0.68a,*,* 0.67b,*,*
Activated Isomorellin 8.00c 10.00c 20.00c
caspase-3 Doxorubicin 8.00c 9.00c 12.00c
Iso + Dox 1.00 32.00c,*,* 36.00c,*,*
IκB-α Isomorellin 1.16a 1.18 1.25b
Doxorubicin 1.16a 1.17 1.21b
Iso + Dox 1.17 1.21 1.40a,*,*
pIκB-α Isomorellin 0.93 0.87 0.02a
Doxorubicin 0.96 0.78 0.02b
Iso + Dox 0.85a 0.73a,*,– 0.02b
NF-κB/p65 Isomorellin 1.00 0.77a 0.01c
Doxorubicin 1.00 1.00 0.87a
Iso + Dox 0.66b 0.02c,*,* 0.01c,–,*
MRP1 Isomorellin 0.97 0.91 0.79b
Doxorubicin 0.97 0.96 0.57b
Iso + Dox 0.81a 0.79a,–,* 0.35c,*,*
Data = The mean ratio of the density readings of target proteins normalized to β-actin from the isomorellin- and/or doxorubicin-treated to DMSO-treated
cells (n = 3). aP < 0.05, bP < 0.01, cP < 0.001 vs. DMSO-treated cells. Comparison between isomorellin or doxorubicin treatment alone and combined drug
treatment indicated by *,*P < 0.05 respectively, not significant difference indicated by “–”.
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Table 4 Fold-change of proteins in forbesione- and/or doxorubicin-treated vs. DMSO-treated KKU-100 cells
Proteins Treatments
KKU-100 cell
Fold-changes of proteins in treated vs. control cells
Concentration of forbesione or doxorubicin (μM)
Forbesione 0.25 0.50 1.00
Doxorubicin 0.006 0.012 0.025
Forb + Dox C1 C2 C3
Bcl-2 Forbesione 0.63a 0.60a 0.27c
Doxorubicin 0.76 0.68b 0.25c
Forb + Dox 0.74a 0.65b,–,* 0.10c,*,*
Bax Forbesione 1.56a 2.06b 2.06c
Doxorubicin 1.87a 2.07a 2.17a
Forb + Dox 2.35c 2.37c,*,* 3.24c,*,*
Bax/Bcl-2 Forbesione 0.53b 0.73a 1.63c
Doxorubicin 0.84a 1.03 2.87c
Forb + Dox 1.18 1.35a,*,– 12.00c,*,*
survivin Forbesione 0.96 0.78a 0.35c
Doxorubicin 1.00 0.97 0.24c
Forb + Dox 0.97 0.41a,*,* 0.13c,*,*
Procaspase-9 Forbesione 0.92 0.79a 0.70a
Doxorubicin 0.90 0.71a 0.65a
Forb + Dox 0.69 0.68 0c,*,*
Activated Forbesione 10.00c 39.00c 42.00c
caspase-9 Doxorubicin 22.00c 48.00c 51.00c
Forb + Dox 50.00c 50.00c,*,– 64.00c,*,*
Procaspase-3 Forbesione 1.00 0.99 0.76a
Doxorubicin 0.98 0.76 0.69a
Forb + Dox 0.97 0.74a,*,– 0c,*,*
Activated Forbesione 9.00c 9.00c 42.00c
caspase-3 Doxorubicin 20.00c 40.00c 50.00c
Forb + Dox 15.00c 47.00c,*,– 54.00c,*,*
IκB-α Forbesione 1.05 1.07 1.15
Doxorubicin 1.03 1.06 1.12
Forb + Dox 1.16a 1.21b,–,* 1.21b,*,*
pIκB-α Forbesione 0.97 0.97 0.14b
Doxorubicin 0.58a 0.58a 0.14b
Forb + Dox 0.25c 0.01c,*,* 0.01c,*,*
NF-κB/p65 Forbesione 1.00 0.78b 0.12b
Doxorubicin 1.00 1.00 1.00
Forb + Dox 0.95 0.01c,*,* 0.01c,*,*
MRP1 Forbesione 0.89a 0.79a 0.71a
Doxorubicin 1.00 0.96 0.82a
Forb + Dox 0.75a 0.74b,–,* 0.34c,*,*
Data = The mean ratio of the density readings of target proteins normalized to β-actin from the forbesione- and/or doxorubicin-treated to DMSO-treated
cells (n = 3). aP < 0.05, bP < 0.01, cP < 0.001 vs. DMSO-treated cells. Comparison between forbesione or doxorubicin treatment alone and combined drug
treatment indicated by *,*P < 0.05 respectively, not significant difference indicated by “–”.
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Figure 5 Effect of isomorellin, forbesione and/or doxorubicin on protein expression in cholangiocarcinoma cell lines. A and C, KKU-M156 cells
treated with DMSO or indicated concentrations of isomorellin and/or doxorubicin; B and D, KKU-100 cells treated with DMSO or indicated
concentrations of forbesione and/or doxorubicin for 48 h. Protein expression of nuclear factor-κB (NF-κB), inhibitor of NF-κB (IκB-α), phosphorylated
IκB-α (pIκB-α) and multidrug resistance-associated protein 1 (MRP1) was determined by Western blot analysis.
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inhibitory activity against the growth of various human
cancer cell lines [29,36] as well as anti-cancer and anti-
tumor activities [37]. We recently demonstrated that four
caged xanthones, isomorellin, isomorellinol, forbesione
and gambogic acid, can induce cell cycle arrest [30] and
apoptotic cell death in CCA cell lines [29].
In the present study, we investigated the combined ef-
fects of two caged xanthones (isomorellin and forbesione)
with doxorubicin in the CCA KKU-100, KKU-M139 and
KKU-M156 cell lines using the median-effect equation
and the CI method. Because the CCA cell lines used in
this study were derived from intrahepatic CCA, which
comes in close contact with normal hepatocytes, Chang(normal hepatocyte) cells were used as controls for the se-
lective cytotoxicity study. We found that isomorellin,
forbesione and doxorubicin alone mediated significant
inhibitory effects on the growth of Chang cells and
KKU-100, KKU-M139 and KKU-M156 cells in a dose-
dependent manner. The inhibitory effects of isomorel-
lin, forbesione and doxorubicin on cell growth were
greater in KKU-M156 cells than in KKU-M139 and
KKU-100 cells, possibly due to the different histologic
types and drug sensitivities of these three cell lines
[14]. The two caged xanthones (isomorellin and forbe-
sione) showed selective growth inhibitory activity in
cancer cells compared with Chang cells. These results
confirm our previous study, which showed that
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growth of CCA cell lines compared to normal human
peripheral blood mononuclear cells [29]. The IC50
values of isomorellin and forbesione reported for
KKU-100 and KKU-M156 cells in this study differed
from those reported previously [29]. This may be due
in part to the different passage numbers of the cell
lines. In the previous study, cells were used at the 20th-
27th passage, while in the present study cells were used at
the 70th-76th passage. Similar to our previous results, the
susceptibility of four human melanoma cell lines to
anthracyclines was much higher at early passages than at
later passages [38]. These results suggest that the activity
of some molecules involved in chemosusceptibility might
be gradually lost during serial passaging.
Doxorubicin is a well-known cancer therapeutic agent
but is highly toxic in normal tissues during cancer ther-
apy [39]. Doxorubicin has harmful effects on health and
can induce primary and secondary drug resistance in
tumor cells, limiting the success of cancer chemotherapy
[5,6]. Combination chemotherapy is a superior modality
of therapy, especially when naturally occurring dietary
supplements (with known anticancer activity) are used to
reduce the systemic toxicity of chemotherapy [40,41]. In
this study, the isomorellin/doxorubicin combination syn-
ergistically enhanced the growth inhibition of KKU-M139
and KKU-M156 cells. A synergistic effect was also demon-
strated after treatment with the forbesione/doxorubicin
combination in KKU-100 and KKU-M139 cells. These
combinations also showed an antagonistic effect in Chang
cells. From the calculated CI values, the combination of
isomorellin/doxorubicin showed the highest synergistic ef-
fect in KKU-M156 cells (CI value at IC90 = 0.24), whereas
the combination of forbesione/doxorubicin showed the
highest synergistic effect in KKU-100 cells (CI value at
IC90 = 0.39). According to these results, the effects of iso-
morellin/doxorubicin in KKU-M156 cells and of forbe-
sione/doxorubicin in KKU-100 cells were selected for
further investigation. These results show that the inter-
action between each caged xanthone and doxorubicin dif-
fered in each CCA cell line. This difference may be due to
the different chemical structures of the two compounds;Figure 6 Chemical structures of the two caged xanthones.although they share a caged structure, a chromene ring is
present in isomorellin but absent in forbesione. Forbe-
sione has two non-functional prenyl side-chains, whereas
one of the two prenyl side-chains of isomorellin is func-
tionalized as an aldehyde (Figure 6). Our results provide
corroborative evidence for the functional differences
between isomorellin and forbesione in terms of their
inhibition of growth in three CCA cell lines. In addition,
the calculated DRIs demonstrated that the combination of
isomorellin/doxorubicin can reduce the effective dose
of doxorubicin for KKU-M156 cells at IC75 and IC90
by 2.18-fold and 4.23-fold, respectively, and for KKU-
M139 cells at IC75 and IC90 by 2.57-fold and 2.17-fold,
respectively (Table 2). Similarly, the combination of
forbesione/doxorubicin could reduce the effective dose
of doxorubicin for KKU-100 cells at IC75 and IC90 by
1.73-fold and 2.99-fold, respectively, and for KKU-
M139 cells at IC75 and IC90 by 5.20-fold and 4.12-fold,
respectively (Table 2). These results indicate the broad
spectrum of the anti-CCA effects of these two combina-
tions. These findings support the hypothesis that combi-
nations of plant compounds and chemotherapeutic drugs
can reduce the concentration of doxorubicin used in treat-
ment, retaining its benefits and minimizing its cytotoxic
effects while enhancing therapeutic efficacy.
Although 5-FU has been used widely for chemother-
apy in patients with CCA [4], our preliminary data show
that the combination of caged xanthones with 5-FU had
an antagonistic effect on the inhibition of the growth of
CCA cell lines (data not shown).
Chemotherapeutic drugs indirectly induce apoptosis
through DNA damage and cell cycle arrest. Doxorubicin
induces tumor cell apoptosis by intercalating into DNA
and inhibiting topoisomerase II [42]. Resistance to anti-
cancer agents is thought to be the failure of these agents
to induce apoptosis [43,44]. Therefore, agents that can
induce apoptosis should improve therapeutic efficacy.
Isomorellin and forbesione are reported to induce cell
cycle arrest at G0/G1 phase [30] and to induce apoptosis
in KKU-100 and KKU-M156 cells [29]. The synergistic
effect of gambogic acid with 5-FU in the induction of
apoptosis was reported in human gastric carcinoma
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morellin and forbesione enhanced apoptosis induced by
doxorubicin in KKU-M156 and KKU-100 cells, respect-
ively (Figure 3).
Several chemotherapeutic drugs induce apoptosis through
a mitochondrial pathway regulated by the Bcl-2-family of
proteins, including pro-apoptotic proteins (i.e., Bax) and
anti-apoptotic proteins (i.e., Bcl-2) [44]. In the current study,
treating KKU-M156 cells with isomorellin and/or doxorubi-
cin or treating KKU-100 cells with forbesione and/or doxo-
rubicin increased the expression of Bax while decreasing the
expression of Bcl-2, leading to an increase in the Bax/Bcl-2
ratio (Figure 4 and Tables 3 & 4). Our results confirm those
of previous studies in which isomorellin, forbesione and
gambogic acid induced apoptosis through the regulation of
Bax (up) and Bcl-2 (down) protein expression in the human
gastric carcinoma cell line MGC-803 [19] and in CCA cell
lines [29].
In the intrinsic apoptotic pathway, an increase in the
Bax/Bcl-2 ratio leads to the release of cytochrome C
from mitochondria; the released cytochrome C then
forms a complex with apoptotic protease activating
factor-1 (Apaf-1) and procaspase-9 (called the apopto-
some), leading to the activation of caspase-9 and caspase-
3 and subsequent apoptotic cell death [45,46]. Survivin is
a human inhibitor of apoptosis proteins (IAP) and inhibits
activated caspase-3 and caspase-7 [47]. In the current
study, treatment of KKU-M156 cells with isomorellin
and/or doxorubicin and treatment of KKU-100 cells with
forbesione and/or doxorubicin decreased the protein ex-
pression of survivin, procaspase-9 and procaspase-3, while
those treatments increased protein expression levels of ac-
tivated caspase-9 and caspase-3. These effects were more
prominent following combination treatment (Figure 4 and
Tables 3 & 4), suggesting that these treatments induced
apoptosis in both CCA cell lines through caspase-9 and
caspase-3 activation. Isomorellin and forbesione induced
apoptosis by decreasing survivin protein expression while
increasing the activation of caspase-9 and caspase-3 in
CCA cells [29]. These results suggest that the synergistic
induction of apoptosis observed following combination
treatment is mediated through a caspase-dependent mito-
chondrial apoptosis pathway.
Alongside the induction of apoptosis, anti-cancer drugs
can suppress tumor growth via the suppression of NF-κB
activation. NF-κB activates the expression of cell survival
regulation genes (anti-apoptotic proteins Bcl-2 and survivin)
and drug resistance genes [33]. NF-κB comprises p50 and
p65 subunits that form an inactive complex with the inhibi-
tor protein IκB in the cytoplasm. Following cellular stimula-
tion, IκB and NF-κB/p65 are phosphorylated by IκB-α
kinase (IKK), leading to IκB degradation [33] and the DNA
binding of NF-κB/p65, which initiates the transcription of
its target genes [33,48]. Doxorubicin inhibits NF-κBactivation in various cell lines [49]. In our previous study,
we found that isomorellin inhibits NF-κB activation in
KKU-100 and KKU-M156 cells by increasing the level of
IκB-α in the cytosol and decreasing the expression and nu-
clear translocation of NF-κB/p65 protein [30]. Therefore, we
theorized that combined treatment involving caged xan-
thones and drugs could suppress the NF-κB pathway. Our
data show that the combination of isomorellin or forbesione
with doxorubicin strongly suppressed NF-κB activation by
decreasing the expression of NF-κB/p65, reducing the level
of pIκB-α, and increasing the level of IκB-α (Figures 5A & B
and Tables 3 & 4). The inhibition of NF-κB activation by
combination treatment was confirmed by a decrease in the
protein expression levels of Bcl-2 and survivin, which are
regulated by NF-κB at the transcriptional level [33].
The enhanced expression of MDRs and MDR-associated
proteins (MRPs) in cancer cells is a major cause of multi-
drug resistance both in vitro and in vivo [13]. P-glycoprotein
(P-gp) and MRP1-3 are known to be overexpressed in CCA
[14,15]. A number of natural products are known to en-
hance the drug-induced cytotoxicity of cancer cells by
modulating drug efflux pathways, such as by decreasing the
expression of the P-gp, MRP1 and MRP2 membrane efflux
pumps [50,51]. Our results demonstrated that the combin-
ation of isomorellin or forbesione with doxorubicin strongly
suppressed MRP1 protein expression compared to treat-
ment with either of the compounds or with drug treatment
alone (Figures 5C & D and Tables 3 & 4). The observed de-
crease in MRP1 protein expression may therefore enhance
drug-induced cytotoxicity by increasing intracellular drug
concentrations.
In this study, we used CCA cells derived from primary
tumors of OV-associated CCAs. It is known that the gene
expression profiles of OV-associated intrahepatic cholan-
giocarcinomas (ICCs) in Thai patients are different from
those of non-OV-associated ICCs in Japanese patients
[52]. Genes involved in xenobiotic metabolism are overex-
pressed in OV-associated ICCs, whereas genes related to
growth factor signaling pathways are overexpressed in
non-OV-associated ICCs. Using exome sequencing, dis-
tinct mutational patterns between OV-related CCAs from
Thailand and non-OV related CCAs from Singapore
(Asia) and Romania (Europe) were reported [53]. BAP1,
IDH1 and IDH2 were more frequently mutated in non-
OV related CCAs, whereas TP53 mutations showed a
reciprocal pattern. As these differences might affect
the sensitivities of CCAs to chemotherapeutic agents,
further study is required to assess the applicability of
the combination of isomorellin or forbesione with doxo-
rubicin for the treatment of non-OV related CCAs.
Conclusions
Our results show that isomorellin and forbesione in com-
bination with doxorubicin can synergistically inhibit growth
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M156 cells. The mechanisms most likely affected by this
treatment are the modulation of apoptosis-regulated pro-
tein expression, the inactivation of NF-κB and the down-
regulation of MRP1 protein expression. Using the same
combinations of drugs, toxicity was not induced in normal
liver cells (Chang cells), suggesting the feasibility of using
these caged xanthones as an adjunct to chemotherapy for
the management of OV-associated CCAs. We also provide
a rationale for further in vivo and clinical studies to deter-
mine the effectiveness of these combinations in the treat-
ment of CCA.
Methods
Plant compounds and chemotherapeutic drug
Two caged xanthones, isomorellin and forbesione (Figure 6),
were isolated from G. hanburyi Hook.f. (family Guttiferae)
[36]. An 8 mM working solution in DMSO was prepared
before use. Injectable doxorubicin (RegNo. 1C 47/50, Batch
No. 7AA014, 2 mg/ml) was kindly provided by Fresenius
Kabi Oncology Ltd. (Hayarna, India). These compounds and
the drug were diluted to the required final concentrations
prior to their use.
Cell culture
CCA KKU-100, KKU-M139 and KKU-M156 cells were
isolated from Thai CCA patients [14,54]. Normal human
liver (Chang) cells were purchased from CLS Cell Lines
Service GmbH (Eppelheim, Germany). Cells were main-
tained at 37°C in a humidified atmosphere containing
5% CO2 in RPMI-1640 medium (Gibco BRL, Grand
Island, NY, USA) supplemented with 10% fetal bovine
serum, 100 units/ml penicillin and 100 μg/ml strepto-
mycin (Gibco BRL).
In vitro cytotoxicity assay
Cells (1 x 105 cells/well) were seeded in 96-well plates for
24 h. Cells were treated for 72 h with compounds or drug
by adding 100 μl/well of each concentration in triplicate
to obtain a final concentration of 0.25-128 μM/well for
each caged xanthone and 0.004-32 μM/well for doxorubi-
cin. Cells treated with 0.1% DMSO were used as a control.
Cell growth was determined using the sulforhodamine B
(SRB) assay [55]. The 50% growth inhibitory concentra-
tions (IC50) of the compounds or drug used on KKU-100,
KKU-M139, KKU-M156 and Chang cells were calculated
from concentration-effect curves after linear regression
analysis. The selectivity of each compound was deter-
mined by its toxicity to each cancer cell line compared to
the Chang cells (i.e., vis-à-vis the respective IC50s).
Evaluation of drug interaction
For combination studies, KKU-100 cells were treated with
isomorellin (0.1, 0.2, 0.4, 0.8 and 1.6 μM) and/ordoxorubicin (0.0078, 0.0156, 0.0313, 0.0625 and 0.125 μM)
or with forbesione (0.0313, 0.0625, 0.125, 0.25, 0.5, 1 and
2 μM) and/or doxorubicin (0.0078, 0.0156, 0.0313, 0.0625,
0.125, 0.25 and 0.5 μM). KKU-M139 cells were treated with
isomorellin (0.125, 0.25, 0.5, 1, 2 and 4 μM) and/or doxo-
rubicin (0.0625, 0.125, 0.25, 0.5, 1 and 2 μM) or with forbe-
sione (0.125, 0.25, 0.5, 1 and 2 μM) and/or doxorubicin
(0.0625, 0.125, 0.25, 0.5 and 1 μM). KKU-M156 cells were
treated with isomorellin (0.0313, 0.0625, 0.125 and
0.25 μM) and/or doxorubicin (0.0391, 0.0781, 0.1563 and
0.3125 μM) or with forbesione (0.0625, 0.125, 0.25, 0.5 and
1 μM) and/or doxorubicin (0.0391, 0.0781, 0.1563, 0.3125
and 0.625 μM). After 72 h, cell growth was examined using
the SRB assay [55]. The Chou et al. median-effect analysis
[31] and the Chou and Talalay combination index (CI)
method [32] were used to determine the synergy, additivity,
or antagonism of the compound-drug combinations [55].
A combination index (CI) of < 1, = 1 or > 1 indicates
synergy, additivity or antagonism, respectively. The dose-
reduction index (DRI) was defined as the degree of dose
reduction possible in a combination for a given degree of
effect compared with the dose of each drug alone [55].
Ethidium bromide/Acridine orange (EB/AO) staining
Apoptosis was determined by the detection of nuclear
morphology using ethidium bromide/acridine orange
(EB/AO) staining [56]. KKU-100 and KKU-M156 cells
(1 x 104 cells/well) were grown in 96-well plates at 37°C
for 24 h and then treated with the studied compounds
combined with doxorubicin at concentrations that showed
a synergistic inhibitory effect on growth for 48 h. Cells
treated with the same concentrations of the compounds or
with doxorubicin alone were also examined. Cells cultured
with 0.1% DMSO were used as controls. The treated cells
were stained with an EB/AO mixture (Sigma Chemical, St.
Louis, MO, USA) and observed under a Nikon fluorescent
microscope. The percentage of apoptotic cells with con-
densed chromatin or fragmented chromatin was calculated
from 500 counted cells.
Protein extraction and Western blot analysis
Cells (1 x 106) were seeded into 10-cm dishes for 24 h
and then treated with 0.1% DMSO or the appropriate
concentrations of the studied compounds and doxorubi-
cin, either alone or in combination, for 48 h. Protein ex-
traction and Western blot analysis were performed [30].
After blocking, the membranes were incubated with pri-
mary antibodies against Bcl-2, Bax, survivin, procaspase-
9, procaspase-3, IκB-α, pIκB-α, NF-κB/p65, MRP1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), activated
caspase-9 (Cell Signaling, Beverly, MA, USA), activated
caspase-3 or β-actin (Sigma Chemical) at 4°C overnight.
The membranes were incubated at room temperature
for 1 h with the horseradish peroxidase-conjugated goat
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(Santa Cruz Biotechnology). The blots were detected by
enhanced chemiluminescence (Pierce Biotechnology,
Rockford, IL, USA) and fluorogrammed with CL-XPosure
film. The intensities of the protein bands were quantified
using Scion Image Software. The relative intensities were
evaluated and normalized to β-actin.
Statistical analyses
Data are expressed as the mean ± standard error (SE).
Student’s t-test was used to compare untreated control
cells with cells treated with compounds and drug alone
or in combination. Differences were considered significant
at aP < 0.05, bP < 0.01 and cP < 0.001. All analyses were
performed using Microsoft Excel (Microsoft, Redmond,
WA, USA).
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